|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600122262 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-10 16:34:25 |
|
注册时间: Date of Registration: |
2026-04-10 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
新型内减张增强系统重建前交叉韧带的多中心、随机、单盲、平行对照的安全性及有效性临床研究 |
|
Public title: |
A Multicenter, Randomized, Single-Blind, Parallel-Controlled Study on the Safety and Efficacy of the Novel Internal Tension-Relieving Augmentation System for Anterior Cruciate Ligament Reconstruction |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
新型内减张增强系统重建前交叉韧带的多中心、随机、单盲、平行对照的安全性及有效性临床研究 |
|
Scientific title: |
A Multicenter, Randomized, Single-Blind, Parallel-Controlled Study on the Safety and Efficacy of the Novel Internal Tension-Relieving Augmentation System for Anterior Cruciate Ligament Reconstruction |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李彦林 |
研究负责人: |
李彦林 |
|
Applicant: |
Yanlin Li |
Study leader: |
Yanlin Li |
|
申请注册联系人电话: Applicant telephone: |
+86 87 65324888 |
研究负责人电话:
Study leader's |
+86 871 65324888 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
liyanlin@kmmu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
liyanlin@kmmu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
云南省昆明市五华区西昌路295号 |
研究负责人通讯地址: |
云南省昆明市西昌路295号 |
|
Applicant address: |
No. 295, Xichang Road, Wuhua District, Kunming City, Yunnan Province |
Study leader's address: |
No. 295, Xichang Road, Wuhua District, Kunming City, Yunnan Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
昆明医科大学第一附属医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Kunming Medical University |
||
|
研究负责人所在单位: |
昆明医科大学第一附属医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Kunming Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2026)伦审L第1号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
昆明医科大学第一附属医院伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics committee of First Affiliated Hospital of Kunming Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-01-08 00:00:00 | ||
|
伦理委员会联系人: |
王婷 |
||
|
Contact Name of the ethic committee: |
Ting Wang |
||
|
伦理委员会联系地址: |
云南省昆明市五华区西昌路295号 |
||
|
Contact Address of the ethic committee: |
No. 295, Xichang Road, Wuhua District, Kunming City, Yunnan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 871 65328584 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
KYFYYEC@163.com |
|
研究实施负责(组长)单位: |
昆明医科大学第一附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
First Affiliated Hospital of Kunming Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
云南省昆明市五华区西昌路295号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 295, Xichang Road, Wuhua District, Kunming City, Yunnan Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
重点研发计划 |
||||||||||||||||||||||
|
Source(s) of funding: |
Key Research and Development Program |
||||||||||||||||||||||
|
研究疾病: |
膝关节前交叉韧带损伤 |
||||||||||||||||||||||
|
Target disease: |
Anterior Cruciate Ligament injury of the knee |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本次临床试验目的是研究并评估新型内减张增强系统辅助前交叉韧带重建的安全性、有效性及临床应用疗效。 |
||||||||||||||||||||||
|
Objectives of Study: |
The purpose of this clinical trial is to investigate and evaluate the safety, efficacy, and clinical outcomes of a novel internal tension-relieving augmentation system in assisting anterior cruciate ligament reconstruction. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.男性或女性,年龄在18岁以上、50岁以下(含18岁和50岁); 2.符合2021年《前交叉韧带损伤治疗国际共识》(ICON)ACL损伤的诊断标准; 3.膝关节前交叉韧带损伤合并半月板损伤; 4.拟行“关节镜下前交叉韧带解剖重建术”的患者; 5.平素体健,无严重慢性病史,能耐受手术者; 6.无患膝关节外合并症,无关节畸形; 7.成年受试者同意参加本试验,并签署“受试者知情同意书”; 8.愿意遵守此研究方案中所规定的禁令与约束; 9.患者自愿,签署知情同意,依从性好 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Male or female, aged 18 to 50 years inclusive. 2.Meet the diagnostic criteria for ACL injury as outlined in the 2021 International Consensus on Anterior Cruciate Ligament Injuries (ICON). 3.Anterior cruciate ligament (ACL) injury of the knee associated with meniscal injury. 4.Patients who are scheduled for arthroscopic anatomical anterior cruciate ligament reconstruction. 5.The patient is generally healthy, has no significant chronic medical history, and is considered able to tolerate the surgical procedure. 6.There are no extra-articular comorbidities or joint deformities. 7.Adult subjects have consented to participate in this trial and have signed the Informed Consent Form. 8.Is willing to comply with all prohibitions and restrictions specified in this study protocol. 9.The patient participated voluntarily, provided signed informed consent, and demonstrated good compliance |
||||||||||||||||||||||
|
排除标准: |
1.合并膝关节感染、痛风性关节炎、类风湿性关节炎; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.including knee joint infection, gouty arthritis, or rheumatoid arthritis. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-09-01 00:00:00至 To 2027-09-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-04-10 00:00:00 至 To 2027-09-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由研究申办方使用计算机程序中的随机数生成功能来产生随机数字或代码。每个参与者被分配一个随机数字或代码,然后根据这些数字或代码将参与者分配到实验组或对照组。确保每个参与者有相等的机会被分配到任意一组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random numbers or codes are generated by the research leader using the random number generation function in a computer program. Each participant was assigned a random number or code, and participants were then assigned to an experimental or control group based on those numbers or codes. Ensure that each participant has an equal chance of being assigned to either group. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
单盲,对研究参与者设盲 |
|
Blinding: |
Single-blind, with the participants of the study remaining unaware of the situation |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |